AgomAb Therapeutics NV Stock Price, News & Analysis
Company Description
Agomab Therapeutics NV (AGMB) develops disease-modifying therapeutics for fibro-inflammatory, immunology, and inflammatory diseases. The company is a clinical-stage biopharmaceutical issuer headquartered in Antwerp, Belgium, and its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol AGMB. Each ADS represents one common share of Agomab.
Agomab's research and development model centers on chronic fibrotic indications and therapies designed to target established biological pathways. Its product candidates use small-molecule and antibody approaches, including organ-restricted strategies intended to focus activity in affected tissues. The company describes its program focus as resolving fibro-inflammation and restoring organ function in diseases associated with fibrosis.
The company's disclosed pipeline includes ontunisertib, also known as AGMB-129, and AGMB-447. Ontunisertib is being developed in fibrostenosing Crohn's disease, a fibrotic complication of inflammatory bowel disease. AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5, also referred to as TGFβR1, in development for idiopathic pulmonary fibrosis. Agomab has reported U.S. composition-of-matter patent coverage for AGMB-447.
As a development-stage biopharmaceutical company, Agomab's operating activity is focused on pre-commercial research and clinical development rather than commercial product sales. Its recurring corporate disclosures address clinical-program progress, intellectual-property protection, regulatory interactions, research and development spending, financing activity, and governance matters. Agomab completed its initial public offering of ADSs in February 2026, establishing AGMB as a publicly traded foreign private issuer in the United States.
Stock Performance
AgomAb Therapeutics NV (AGMB) stock last traded at $10.55, down 4.80% from the previous close. Over the past 12 months, the stock has lost 28.0%. At a market capitalization of $543.7M, AGMB is classified as a small-cap stock with approximately 49.2M shares outstanding.
AGMB Rankings
Latest News
AgomAb Therapeutics NV has 5 recent news articles, with the latest published 3 days ago. Of the recent coverage, 1 article coincided with positive price movement and 3 with negative movement. Key topics include earnings, IPO, offering. View all AGMB news →
SEC Filings
AgomAb Therapeutics NV has filed 5 recent SEC filings, including 3 Form SCHEDULE 13G, 1 Form 6-K, 1 Form 20-F. The most recent filing was submitted on May 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AGMB SEC filings →
Financial Highlights
Upcoming Events
Initiate two Phase 2 studies
Topline OLE and IPF data
Phase 1b patient results
AgomAb Therapeutics NV has 3 upcoming scheduled events. The next event, "Initiate two Phase 2 studies", is scheduled for July 1, 2026 (in 45 days). Investors can track these dates to stay informed about potential catalysts that may affect the AGMB stock price.
Short Interest History
Short interest in AgomAb Therapeutics NV (AGMB) currently stands at 433.3 thousand shares, up 68.5% from the previous reporting period, representing 0.9% of the float. Over the past 12 months, short interest has increased by 267.1%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for AgomAb Therapeutics NV (AGMB) currently stands at 2.1 days, up 58.5% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 106% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.1 days.
AGMB Company Profile & Sector Positioning
AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,164 among all tracked companies.